A carregar...
Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma
BACKGROUND & OBJECTIVES: Inhibitors of immune checkpoint regulators, programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1), improve outcome in advanced non-small-cell lung carcinoma (NSCLC). Tumours expressing PD-L1 protein are more likely to benefit from this targeted therapy. Multipl...
Na minha lista:
| Publicado no: | Indian J Med Res |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer - Medknow
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6902360/ https://ncbi.nlm.nih.gov/pubmed/31823919 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/ijmr.IJMR_367_18 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|